Tsubasa Aoki
Research Scientist Ajinomoto Co., Inc.
Seminars
Wednesday 29th July 2026
Unlocking the Full Potential of Antibody-Based Conjugates through AJICAP® Site-Specific Conjugation and Linker Technologies
2:00 pm
- AJICAP® Conjugation: Leveraging Site-Specific Technologies in Next-Generation ADCs to Enhance Clinically Relevant Biological Properties through Precise DAR Control.
- AJICAP® Linker: Demonstrating a Novel Hydrophilic Linker Technology that Enhances Stability and Enables Versatile Synthesis of ADCs with Higher DAR.
- AJICAP-derived ADCs Exhibiting High In-Vivo Stability in NHP Studies, Supporting their Suitability for Further Development.
- Beyond Conventional ADCs: Site-Specific Conjugation of Bispecific Antibodies and Antibody–Oligonucleotide Conjugates
